Posted by Michael Wonder on 30 Jan 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
28 January 2022 - The positive opinion is based on the landmark EMPEROR-Preserved Phase 3 trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%.
The CHMP of the EMA has granted a positive opinion recommending Jardiance (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.
